MetaCap

Bambusa Therapeutics (BBTX) vs Prime Medicine (PRME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $791.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%PRME-24.79%
+16%-5%-27%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%PRME-24.79%
+9%-9%-26%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus PRME key metrics
MetricBBTXPRME
Share price$16.00$3.55
Market cap$815.08M$791.62M
1-day change+2.89%-7.55%
YTD return—+2.31%
1-year return—-2.20%
EPS (TTM)$-1.73$-0.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.63M
Revenue growth (YoY)—+55.28%
Net income (latest FY)—$-201.14M
Operating margin—-4498.06%
Net margin—-4342.44%
52-week high$17.65$5.91
52-week low$13.60$2.67
Distance from 52-week high-9.35%-39.93%
Analyst consensus—buy
Avg. price target upside—+108.17%
Average volume359.41K4.64M
Shares outstanding50.94M222.99M
Employees26146
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About Prime Medicine

PRME stock →

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees

BBTX vs PRME FAQ

Which is bigger, Bambusa Therapeutics or Prime Medicine?

Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $791.62M for Prime Medicine (PRME).

Are Bambusa Therapeutics and Prime Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons